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Background
Rupatadine is an anti-H1/PAF antagonist that has proven
to be effective and safe in adults/adolescents for Allergic
Rhinitis (AR) and Urticaria. In addition, Rupatadine has
been recently licensed for the symptomatic treatment of
AR in children aged 6-11 years. The aim of this study was
to assess the efficacy and safety of Rupatadine oral solution
in children with Chronic Spontaneous Urticaria (CSU).
Methods
A randomized, double blind, multicenter, parallel group,
placebo and active controlled clinical trial was conducted
in children aged 2-11 year suffering from CSU. Patients
were randomly allocated to one of the treatment groups:
Rupatadine 1mg/mL, Desloratadine 0.5mg/ml, or placebo
oral solutions. Dosing was done according to patients’
weight (2.5 ml > 10 Kg - 25 Kg or 5 ml > 25 Kg). Patients
received the study medication during 6 weeks (42 days)
and symptoms were scored daily in the patient diary.
There was a safety follow up period of 6 weeks (42 days)
after the end of treatment. The primary efficacy variable
was the change in the 7-day cumulative children adapted
Urticaria Activity Score (UAS7) over the treatment period.
Other efficacy assessments included the mean number of
wheals (MNW) score, mean pruritus (MPS) score and
Children Dermatology Life Quality Index (CDLQI).
Adverse events were recorded through the study (84 days).
Results
A total of 199 patients were included in the ITT analysis:
63 in the Rupatadine group, 69 in the Desloratadine
group, and 67 in the placebo group. The UAS7 was found
to be significantly reduced in the Rupatadine group
(-55.8%; p=0 .001) and the Desloratadine group (-48.4%;
p= 0.013) as compared to placebo (-30.3%). Also, CDLQI
scores were significantly improved in both active treat-
ment groups as compared to placebo. The overall inci-
dence of adverse events was similar among treatments
groups.
Conclusion
Rupatadine, in accordance with the current CSU guideline
recommendations, is an effective and safe choice in CSU
in 2-11 yr children.
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